Sugi Predict

Sugi Predict / Compounds / SCHEMBL4565838

SCHEMBL4565838

SCHEMBL4565838

CSc1ncc2cc(-c3ccc(F)c(NC(=O)Nc4cccc(C(F)(F)F)c4)c3)c(=O)n(C)c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 1/20 0.46
▸ RIPK1 Q13546 9/20 0.44
▸ KDR P35968 6/20 0.44
▸ LCK P06239 4/20 0.44
▸ JAK3 P52333 2/20 0.44
▸ MAPK14 Q16539 2/20 0.44
▸ TEK Q02763 1/20 0.44
▸ ABL1 P00519 2/20 0.43
▸ FYN P06241 2/20 0.43
▸ CSF1R P07333 2/20 0.43
▸ LYN P07948 2/20 0.43
▸ KIT P10721 2/20 0.43
▸ SRC P12931 2/20 0.43
▸ FLT1 P17948 2/20 0.43
▸ FLT4 P35916 2/20 0.43
▸ FLT3 P36888 2/20 0.43
▸ BLK P51451 2/20 0.43
▸ TRPV1 Q8NER1 1/20 0.43
▸ DDR2 Q16832 1/20 0.42
▸ NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4552420 0.94 BRAF (0.41) SYKRIPK1KDRLCKJAK3
SCHEMBL5062417 0.89 LCK (0.55) SYKRIPK1KDRLCKJAK3
SCHEMBL5065474 0.89 WEE1 (0.45) SYKRIPK1KDRMAPK14ABL1
SCHEMBL5061370 0.88 SYK (0.52) SYKKDRLCKJAK3MAPK14
SCHEMBL5057372 0.88 LCK (0.55) SYKRIPK1KDRLCKJAK3
SCHEMBL5065413 0.86 NTRK1 (0.45) KDRLCKMAPK14TEKABL1
SCHEMBL5057707 0.86 KDR (0.44) KDRLCKABL1CSF1RLYN
SCHEMBL5057551 0.85 WEE1 (0.41) KDRMAPK14NPC1MAPTWEE1
SCHEMBL5062999 0.84 SYK (0.48) SYKRIPK1KDRLCKJAK3
SCHEMBL4552482 0.83 SYK (0.48) SYKRIPK1KDRLCKJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 — — US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 — — US disclosed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 — — EP disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 — — US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 SYK 898/4885RIPK1 151/4885KDR 500/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 SYK 898/4885RIPK1 151/4885KDR 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.